Adam Frome, MD
Nephrology · The Woodlands, TXNPI 1215124417
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,215, more than ten times the $54 reported in 2019.
Across 256 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$587
- Travere Therapeutics, Inc.$528
- Amgen$396
- Novartis$392
- Calliditas Therapeutics US Inc.$330
- plus $2K from 23 others
Across 324 payments — averaging $9715.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$903K
- CSL Behring$745K
- Astrazeneca UK Limited$438K
- Vertex$415K
- AstraZeneca$323K
- Boehringer Ingelheim International GmbH$88K
- plus $235K from 5 others
What the payments were for
- Food & beverage$5,767100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,226 |
| Otsuka America Pharmaceutical, Inc. | 28 | $587 |
| Travere Therapeutics, Inc. | 16 | $528 |
| Amgen(2 entities) | 19 | $396 |
| Novartis | 18 | $392 |
| Calliditas Therapeutics US Inc. | 14 | $330 |
| Vifor Pharma, Inc. | 15 | $289 |
| Mallinckrodt Hospital Products Inc. | 8 | $288 |
| Bayer | 21 | $286 |
| Novo Nordisk | 10 | $219 |
| GSK | 9 | $203 |
| Recor Medical Inc | 7 | $151 |
| Lilly USA, LLC | 7 | $136 |
| Scpharmaceuticals Inc. | 5 | $110 |
| ANI Pharmaceuticals, Inc. | 4 | $101 |
| Aurinia Pharma U.S., Inc. | 5 | $93 |
| Kyowa Kirin, Inc. | 3 | $60 |
| Ardelyx, Inc. | 2 | $52 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Medtronic | 1 | $43 |
| Renalytix AI, Inc. | 2 | $39 |
| Sanofi | 2 | $39 |
| Fresenius USA Marketing, Inc. | 1 | $36 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Boehringer Ingelheim | 1 | $21 |
| Akebia Therapeutics Inc | 1 | $21 |
| AbbVie | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,779 in reported general payments places this provider in the 80th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 180 | $180,708 |
| KerendiaFinerenone | 98 | $118,467 |
| JardianceEmpagliflozin | 57 | $66,067 |
| OzempicSemaglutide | 42 | $63,183 |
| XphozahTenapanor Hcl | 14 | $37,317 |
| VeltassaPatiromer Calcium Sorbitex | 25 | $35,717 |
| MounjaroTirzepatide | 16 | $20,202 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $14,963 |
| MyrbetriqMirabegron | 21 | $11,236 |
| VascepaIcosapent Ethyl | 16 | $8,351 |
| RetacritEpoetin Alfa-Epbx | 23 | $8,143 |
| Ethacrynic Acid | 14 | $7,904 |
| Bumetanide | 97 | $6,505 |
| Sevelamer Carbonate | 41 | $5,870 |
| Nifedipine ErNifedipine | 127 | $5,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,226 | $195,671200 claims |
| BayerKerendia | $286 | $118,46798 claims |
| Boehringer IngelheimJardiance | $21 | $66,06757 claims |
| Novo NordiskOzempic | $219 | $63,18342 claims |
| Lilly USA, LLCMounjaro | $136 | $20,20216 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $101 | $55219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,070 nephrology providers in Texas.
Other nephrology in The Woodlands
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.